Join the movement
We can change the trajectory of colorectal cancer together.

Seeking collaborative researchers
Project Cure CRC is a multi-faceted effort combining innovative research and cutting-edge venture philanthropy. Ending colorectal cancer will take all of us, in collaboration, driving urgently toward cures.
Direct funding
Project Cure CRC’s fund for breakthoughs supports science from a wide variety of researchers.
Young Investigator Accelerator Award
Supports early-career faculty with innovative ideas in CRC research, providing up to $200,000 over two years for original preclinical, translational, or early clinical projects.
Senior Investigator Accelerator Award
Funds transformative research to advance CRC therapies, offering up to $500,000 over two years for senior investigators proposing localized or metastatic CRC projects.
Pilot Accelerator Award
Encourages high-risk, high-reward CRC research with clear hypotheses, providing up to $200,000 over two years to establish proof-of-concept.
Team Science Accelerator Award
Supports collaborative, multidisciplinary CRC research teams with up to $500,000 over two years to drive curative science and innovation.
Opportunistic Award
Provides up to $500,000 for small startup companies (with one or less rounds of funding) conducting novel CRC research over one year to advance curative science.
Innovators wanted
Project Cure CRC prioritizes high-risk/high-reward proposals that fast-track research toward curative solutions, with a strong preference for collaborative and public-private partnerships.
Sponsors
Up Next
Funded researchTop resources

Alliance Presents Project Cure CRC Posters at AACR & Awards New Grants
Project Cure CRC funds cutting-edge colorectal cancer (CRC) research and aims to improve patient outcomes through its dynamic patient navigation portal, BlueHQ.org.

Alliance Survey Reveals Disparities in Minorities that Could Increase Colorectal Cancer Risk
Minority groups are significantly less aware that colorectal cancer is often not detected until the late stages due to mild symptoms.

NIH: Combination immunotherapy shrank GI cancers
A new kind of tumor infiltrating lymphocyte (TIL) therapy improved the treatment’s effectiveness in patients with metastatic GI cancers.